Latest Immunosuppressants Stories
However, Platform Injectables Continue to Represent the Majority of Recent MS Prescriptions, According to Findings from Decision Resources Group BURLINGTON, Mass., Nov.
U.S. Court of Appeals for the Federal Circuit Concurrently Affirms Denial of Antares Pharma's Motion to Prohibit the Marketing of Rasuvo CHICAGO, Nov.
Right the Wrong Campaign seeks to educate Canadians on how a government approved drug left them with severe birth defects that challenge their lives to this day MONTREAL, Nov.
CHENÔVE, France, November 24, 2014 /PRNewswire/ -- - The needle-free injection with ZENEO(R) Methrotrexate produces similar blood levels to the
ReportsnReports.com adds Rheumatoid Arthritis Global Clinical Trials Review H2 2014 to its store.
EVOLVE II Trial Represents the First Successful U.S. Pivotal Trial of a Bioabsorbable Polymer Stent MARLBOROUGH, Mass., Nov. 19, 2014 /PRNewswire/ -- In the first successful U.S.
- Study published in American Journal of Transplantation - HORSHOLM, Denmark, Nov.
- Secukinumab met primary endpoints demonstrating statistically significant improvements versus placebo in signs and symptoms of active psoriatic arthritis (PsA) in two pivotal Phase III studies
Sales of Biologics Will Contribute Approximately $2.3 Billion to the UC Market in 2023, According to Findings from Decision Resources Group BURLINGTON, Mass., Nov.
Brodalumab Meets All Primary and All Key Secondary Endpoints THOUSAND OAKS, Calif. and LONDON, Nov.
- Emitting flashes of light; glittering.